Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

EYLEA HD - Health Canada Drug Approval Details

Approvals/Health Canada/EYLEA HD

Authorized

STANDARD

EYLEA HD

Bayer Inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 86c31626e2ff1df0
Company: Bayer Inc
Type: Standard

Approval Details

Approval Id: 86c31626e2ff1df0
Drug Approval Canada Name: EYLEA HD
Product Name: EYLEA HD
Status: Marketed
Status Date: 2025-04-07
Original Market Date: 2025-04-07
Din: 02554798
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravitreal
Schedule: Prescription , Schedule D
Ahfs: 52:92.00
Atc Original: S01LA05 AFLIBERCEPT
Atc Name: s 01 la 05
Aig Number: 0154950003
Company Name: Bayer Inc
Company Address: 2920 Matheson Blvd East, Mississauga, Ontario, Canada, L4W 5R6

Active Ingredients

AFLIBERCEPT

8 MG / 0.07 ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

86c31626e2ff1df0

Type

Standard

Back to Health Canada Approvals